Rose McNulty

Two-thirds of patients had leftover pills, and some used opioids beyond guideline-recommended durations, an FDA-backed study found.

A new review suggests molecular biomarkers could help gauge lung cancer recurrence risk and guide surveillance, but the evidence is still thin.

Enlicitide, a macrocyclic peptide that binds PCSK9 and blocks LDL receptor interaction, is the first oral PCSK9 inhibitor FDA-approved to lower LDL-C.

Racial gaps in cancer mortality narrowed sharply since the 1990s, led by declines in certain cancer types, but disparities remain.

A cost analysis of nearly 30,000 anti-VEGF visits found travel and missed work, not drug price, drive most of patients' out-of-pocket burden.

Adding thoracic radiotherapy to atezolizumab maintenance tripled serious side effects in small cell lung cancer without improving survival, a trial found.

Genomic testing among Medicare beneficiaries with cancer rose from 6% in 2016 to 16.7% in 2023, though NGS use stayed low, a study found.

Phase 3 trials showed improvements in daytime wakefulness, cataplexy, and the disorder's full symptom range, including sleep paralysis and hallucinations.

Medicaid expansion was linked to improved insurance coverage, earlier diagnosis, and better survival for NSCLC patients, especially in underserved areas.

A pilot combining AI screening with structured nodule follow-up found early lung cancer in 1.6% of flagged patients.